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ABSTRACT
To develop a clinical practice guideline for vaccination in patients with autoimmune 
inflammatory rheumatic disease (AIIRD), the Korean College of Rheumatology and the 
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Korean Society of Infectious Diseases developed a clinical practice guideline according to 
the clinical practice guideline development manual. Since vaccination is unlikely to cause 
AIIRD or worsen disease activities, required vaccinations are recommended. Once patients 
are diagnosed with AIIRD, treatment strategies should be established and, at the same time, 
monitor their vaccination history. It is recommended to administer vaccines when the disease 
enters the stabilized stage. Administering live attenuated vaccines in patients with AIIRD 
who are taking immunosuppressants should be avoided. Vaccination should be considered 
in patients with AIIRD, prior to initiating immunosuppressants. It is recommended to 
administer influenza, Streptococcus pneumoniae, hepatitis A, hepatitis B, herpes zoster, measles-
mumps-rubella virus, human papillomavirus, and tetanus-diphtheria-pertussis vaccines in 
patients with AIIRD; such patients who planned to travel are generally recommended to be 
vaccinated at the recommended vaccine level of healthy adults. Those who live in a household 
with patients with AIIRD and their caregivers should also be vaccinated at levels that are 
generally recommended for healthy adults.
Keywords: Autoimmune inflammatory rheumatic disease; Vaccine; Immunization; Guideline
INTRODUCTION
Autoimmune inflammatory rheumatic disease (AIIRD) involves various organs due to immune 
dysregulation; although, causes have not been identified. In general, patients with AIIRD are 
at relatively high risk for infectious diseases compared to the general population [1-4]. This is 
due to loss of the normal immune response in the pathogenesis of the disease itself but is also 
associated with drug-related factors, such as glucocorticoid and other immunosuppressants, 
during treatment. In addition, comorbidities, such as Felty's syndrome and interstitial 
pneumonia, and disabilities caused by the diseases or operations are also identified as risk 
factors. As the causes of the diseases have recently started to be discovered, targeted therapies, 
such as biologic agents and small molecule inhibitors, have been developed and widely used 
which may increase the possibility of new opportunistic infections that are different from what 
are related to conventional immunosuppressants [5, 6].
In general, vaccination is one of the most effective methods for preventing infectious 
diseases. However, patients with AIIRD have not been adequately vaccinated to date despite 
their necessity [7, 8]. The most significant reason is potentially the lack of understanding 
of the necessity of vaccination among healthcare providers who treat the disease and the 
patients. Although they understand the necessity, there seems to be concern regarding the 
possibility that vaccination can worsen the AIIRD's' activity or that vaccination may not be 
effective for patients with AIIRD to acquire adequate immunity. Numerous clinical practice 
guidelines have been published around the world to promote the interest of doctors and 
patients and raise their awareness regarding the latest knowledge. Many efforts have been 
made to inform the global medical community regarding the latest information on the 
vaccination of patients with AIIRD and induce suitable changes in practice patterns.
In line with changes in clinical settings and the trends in the development of practice 
guidelines at home and abroad, there has also been a growing need for a practice guideline 
for vaccinating patients with AIIRD in Korea considering its health care system, practice 
patterns, and environmental characteristics. To develop a practice guideline for vaccination, 
the Korean Society of Infectious Diseases (KSID) and the Korean College of Rheumatology 
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(KCR) formed a vaccination guideline development committee composed of rheumatologists 
who diagnose and treat AIIRD, vaccine experts, and research methodologists. The total time 
for the guideline to be developed was 2 years and 6 months, between June 2017 and December 
2019. This guideline is intended for experts in rheumatology and infectious diseases and 
for primary care providers who encounter patients with AIIRD intending to inform them of 
primary vaccines, methods to administer vaccines, and considerations in vaccination.
DEVELOPMENT OF CLINICAL GUIDELINE
1. Determination of targeted patients and vaccines of practice guideline
The targeted patients of this practice guideline include adults with AIIRD who are aged 
≥19 years excluding children while targeting the following AIIRD diseases: rheumatoid 
arthritis; systemic lupus erythematosus; antiphospholipid syndrome; adult still's disease; 
systemic sclerosis; scleroderma; relapsing polychondritis; polymyalgia rheumatica; mixed 
connective tissue disease; spondyloarthritis; Behcet's disease; vasculitis; granulomatosis 
with polyangiitis (Wegener's granulomatosis); eosinophilic granulomatosis with 
polyangiitis (Churg-Strauss syndrome); polyarteritis nodosa; Takayasu's arteritis; giant 
cell arteritis; Goodpasture syndrome; cryoglobulinemic vasculitis; dermatomyositis; 
polymyositis; amyopathic dermatomyositis; inclusion body myositis; antisynthetase 
syndrome; eosinophilic myositis; eosinophilic fasciitis; psoriatic arthritis; and periodic fever 
syndrome. The vaccines included in this practice guideline were limited to those primarily 
recommended for adults as follows: influenza vaccine; pneumococcal vaccine; hepatitis 
B vaccine; hepatitis A vaccine; human papillomavirus (HPV) vaccine; tetanus-diphtheria-
pertussis vaccine; herpes zoster vaccine; and measles-mumps-rubella (MMR) vaccine.
2.  Formation of the practice guideline development committee and the 
working committee
A practice guideline development committee was formed, composed of four rheumatologists, 
four infectious disease specialists, and one preventive medicine specialist to determine 
targeted patients and vaccines, discuss methods to develop a detailed practice guideline, 
and key questions. A separate working committee was also formed, composed of seven 
rheumatologists and seven infectious disease specialists, to review key questions related to 
each vaccine and develop recommendations. Those with a conflict of interest to any vaccine 
product were excluded from the committees.
As no sufficient evidence of the efficacy and safety of vaccination of patients with AIIRD was 
available, existing evidence-based practice guidelines were adapted. Additionally, to provide 
up-to-date information, we reviewed and incorporated the results of studies that were 
published after the search period of the most recent guideline. The additionally reviewed 
knowledge was limited to vaccines that have been recently and actively researched including 
the pneumococcal, HPV, and tetanus-diphtheria-pertussis vaccines. This practice guideline 
was developed as per the clinical practice guideline development manual distributed by the 
National Evidence-based healthcare Collaborating Agency [9].
3. Selection of key questions for practice guideline
Key questions were developed by the practice guideline development committee through 
discussion based on questions that can be raised in clinical settings, and the developed key 
questions were divided into general questions related to vaccination and specific questions 
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on individual vaccines. At first, 14 general questions about vaccination and 19 questions about 
individual vaccines were developed. Since the answers to some questions were not supported 
by evidence, existing practice guidelines and studies were reviewed and 18 key questions were 
selected and revised. They were secondarily reviewed by the Working Committee, and the 
final 15 key questions were selected considering the existence of evidence for the questions 
and their applicability in Korea (Table 1).
4. Searches and selection of existing practice guidelines
Practice guidelines were searched using combinations of keywords including vaccine, 
autoimmune inflammatory rheumatic disease and medication. Search terms included the 
following vaccines: influenza vaccine; pneumococcal vaccine; hepatitis B vaccine; hepatitis 
A vaccine; HPV vaccine; tetanus-diphtheria-pertussis vaccine; herpes zoster vaccine; and 
MMR vaccine. The rheumatoid diseases included in this guideline are as follows: rheumatoid 
arthritis; systemic lupus erythematosus; antiphospholipid syndrome; adult still's disease; 
systemic sclerosis; scleroderma; relapsing polychondritis; polymyalgia rheumatica; mixed 
connective tissue disease; spondylarthritis; Behcet's disease; vasculitis; granulomatosis with 
polyangiitis (Wegener's granulomatosis); eosinophilic granulomatosis with polyangiitis 
(Churg-Strauss syndrome); polyarteritis nodosa; Takayasu's arteritis; giant cell arteritis; 
Goodpasture syndrome; cryoglobulinemic vasculitis; dermatomyositis; polymyositis; 
amyopathic dermatomyositis; inclusion body myositis; antisynthetase syndrome; 
eosinophilic myositis; eosinophilic fasciitis; psoriatic arthritis; and periodic fever syndrome. 
The drugs included in this guideline are: disease-modifying antirheumatic drugs (DMARD); 
tumor necrosis factor-alpha (TNF-α) blocking agent; glucocorticoid; methotrexate; 
sulfasalazine; leflunomide; hydroxychloroquine; azathioprine; mycophenolate; cyclosporine; 
cyclophosphamide; tacrolimus; cyclophosphamide; infliximab; etanercept; abatacept; 
adalimumab; golimumab; rituximab; belimumab; tocilizumab; certolizumab; ustekinumab; 
canakinumab; and anakinra. The documents published between January 2010 and August 
2018 were searched and a total of 13 practice guidelines written in English were obtained 
from websites including PubMed, OVID-EMBASE, and Guidelines International Network.
We reviewed the content of 13 practice guidelines to preliminarily determine whether they 
fit the criteria to be included in the development of this practice guideline. Out of a total 
of 13 practice guidelines, five that were solely limited to medicines, and two that were 
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Table 1. List of Key Questions
Key Question 1. Does vaccination aggravate autoimmune inflammatory rheumatic disease (AIIRD)?
Key Question 2. Are live attenuated vaccines safe for patients with AIIRD?
2-1. Are live attenuated vaccines safe for patients who do not receive immunosuppressive therapies?
2-2. Are live attenuated vaccines safe for patients who receive immunosuppressive therapies?
Key Question 3. Is a survey on the vaccination history of AIIRD patients helpful in establishing treatment strategies?
Key Question 4. When should vaccines be administered to patients with AIIRD considering their treatment status?
Key Question 5. Is vaccination helpful in preventing endemic diseases for patients with AIIRD contemplating international travel?
Key Question 6. Should those who live in household members with patients with AIIRD and their caregivers receive vaccines?
Key Question 7. Are the vaccines recommended to patients with AIIRD and administering each vaccine safe and effective?
7-1. Are influenza vaccines safe and effective?
7-2. Are pneumococcal vaccines safe and effective?
7-3. Are hepatitis B vaccines safe and effective?
7-4. Are hepatitis A vaccines safe and effective?
7-5. Are human papillomavirus vaccines safe and effective?
7-6. Are tetanus-diphtheria-pertussis vaccines safe and effective?
7-7. Are herpes zoster vaccines safe and effective?
7-8. Are measles-mumps-rubella vaccines safe and effective?
mainly focused on healthy individuals, rather than vaccination of patients with AIIRD, were 
excluded. Then, a secondary screening was performed on the guidelines that were initially 
searched to identify the authors, whether they were evidence-based guidelines, and whether 
the recommendation grades were described. For each practice guideline, three guideline 
development and working committee members, using the Appraisal of Guidelines Research 
and Evaluation (AGREE) II, an appraisal tool for practice guidelines, scored the following 
items: their scope and objective; management of conflicts of interest; rigidity of development; 
clarity of expressions; applicability; and independence of editing. Based on the results, a total 
of six practice guidelines suitable for adaptation were finally selected (Fig. 1, Table 2).
5.  Review of the procedure for writing the practice guideline and up-to-
datedness
The practice guideline development committee, comprehensively reviewed and collected 
recommendations provided in the selected six practice guidelines focusing on the 
key questions selected by the committee, while the working committee described 
recommendations for key questions and their evidence, based on the collected content and 
the latest studies. The level of evidence (LOE) of each recommendation was graded following 
the GRADE (Grading of Recommendations Assessment, Development and Evaluation) 
methodology into high, moderate, low and very low, and the strength of recommendation 
(SOR) was classified into strong recommendation, weak recommendation, weak against, and 
strong against (Table 3, 4).
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Final practice guidelines (n = 6)
Practice guidelines selected after reviewing
the whole content of guidelines (n = 6)
Practice guidelines searched using PubMed,
OVID-EMBASE, and Guidelines International
Network (n = 13)
Mainly focused on medicines (n = 5)
Mainly focused on healthy persons (n = 2)
Documents excluded after discussion
using AGREE II (n = 0)
Figure 1. Procedure for searching and screening literature for adapting a practice guideline. 
AGREE, appraisal of guidelines research and evaluation.
Table 2. Final practice guidelines selected through an appraisal using AGREE II
Title Country/
area
Organization Year of 
publication
1 EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic 
diseases
Europe European League Against 
Rheumatism
2011
2 Canadian Rheumatology Association Recommendations for the Pharmacological Management of 
Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs: Part II Safety
Canada Canadian Rheumatology 
Association
2012
3 Clinical Practice Guideline for Vaccination of the Immunocompromised Host U.S.A Infectious 2013
Diseases Society of America
4 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis U.S.A American College of 
Rheumatology
2015
5 Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases Switzerland The Federal Commission for 
Swiss Vaccination Issues
2015
6 Recommendations for Vaccination in Adult Patients with Systemic Inflammatory Rheumatic Diseases 
from the Portuguese Society of Rheumatology
Portugal Portuguese Society of 
Rheumatology
2016
AGREE, appraisal of guidelines research and evaluation; EULAR, european league against rheumatism.
An additional literature review was conducted on the pneumococcal, HPV, and tetanus-
diphtheria-pertussis vaccines, out of the eight vaccines addressed in this guideline because 
they have been actively researched on the targets of vaccines, immunogenicity, changes in 
vaccination methods and new vaccines. PubMed and EMBASE were used to search for data. 
Since the selected six practice guidelines were searched among publications released by 
October 2014, those published between November 2014 and October 2018 were additionally 
searched to review their up-to-datedness. We limited our search to systematic reviews, 
randomized controlled studies, cohort studies, case-control studies, and guidelines written 
in English. We applied the same keywords used to search the practice guidelines mentioned 
above. The title and abstract of the searched studies were reviewed by the practice guideline 
development committee and their fitness for this study's purpose was cross-confirmed 
by two individuals. Those that failed to reach consensus were reviewed by two individuals 
together to determine whether to include them. Out of 445 studies first searched regarding 
the pneumococcal vaccine, six were included in the final review; out of 902 studies regarding 
the HPV vaccine, seven were included; out of 925 studies regarding the tetanus-diphtheria-
pertussis vaccine, six were included. The selected studies were transferred to the working 
committee to be utilized in writing this practice guideline (Table 5).
6. Survey on consensus of recommendations in the practice guideline
Data on general recommendations for vaccination and recommendations for each vaccine 
were shared online among 23 members of the practice guideline development and working 
committees who reviewed them. To reach a consensus on each recommendation among 
them, face-to-face meetings were additionally held. Prior to building consensus, it was 
confirmed whether those involved in the development of this guideline had received 
support regarding the targeted vaccines and medications. They expressed agreement and 
disagreement based on the existing practice guidelines, the latest findings, the current status 
of the Korean medical services, the benefits of the vaccines, and abnormal responses. They 
scored their agreement with each recommendation using a 9-point scale; when the score of 
over 80% of committee members reached between 7 - 9 points, it was considered that the 
recommendation reached a consensus. When they failed to reach a consensus on a certain 
recommendation, they revised and adjusted its strength through discussion, ultimately 
voting on a new recommendation to reach a consensus.
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Table 3. Definition of Level of Evidence (LOE)
Level of Evidence Description
High Very unlikely to change confidence in the estimate of effect by an additional study
Moderate Likely to change confidence in the estimate of effect by an additional study
Low Highly likely to change confidence in the estimate of effect by an additional study
Very low Not sure about confidence in the estimate of effect
Table 4. Definition of Strength of Recommendation (SOR)
Strength of Recommendation Description
Strong recommendation Recommended to follow the course of action because there is sufficient evidence of desirable effects
Weak recommendation Recommended to conditionally provide the course of action (test) or to provide it for certain individuals at the discretion of 
specialty providers
Weak against Recommended not to follow the course of action, if feasible, because there is some evidence of undesirable effects
Strong against Recommended not to follow the course of action because there is sufficient evidence of undesirable effects
7. Final review, approval, and distribution of the practice guideline
The developed practice guideline was reviewed and approved by the external examiners 
selected by the KCR and the KSID. To receive feedback from patients with AIIRD who were 
vaccination targets, the guideline was shared with the Association of RA (Rheumatoid 
Arthritis), SLE (Systemic Lupus Erythematosus), AS (Ankylosing Spondylitis) Patients. The 
KCR and KSID agreed to jointly publish and distribute the final practice guideline. This 
guideline will be updated after 5 years according to newly published guidelines and studies.
GENERAL RECOMMENDATIONS
The possibility that vaccination causes AIIRD is low; however, autoimmune responses such 
as Guillain–Barré syndrome and idiopathic thrombocytopenic purpura (ITP) were reported 
after vaccination. It has been rarely reported that adjuvants can be a potential cause of 
AIIRD [10-17]. The majority of studies, however, have reported that vaccines can be safely 
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Table 5. The literature reviewed to reflect the latest knowledge
Title Study design Year of 
publication
1 Immunizations following solid-organ transplantation Review 2014
2 Immunogenicity and safety of the bivalent human papilloma virus (HPV) vaccine in female patients with 
juvenile idiopathic arthritis: a prospective controlled observational cohort study
Case-control study 2014










5 The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to 
non-vaccinated inflammatory arthritis patients
Case-control study 2015
6 The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine 
immunization and subsequent pneumococcal infection in chronic arthritis patients
Case-control study 2015
7 HPV vaccine trials and tribulations: Clinical perspectives Review 2015
8 Pertussis Prevalence in Korean Adolescents and Adults with Persistent Cough Retrospective 
observation study
2015
9 Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis 
patients treated with etanercept
Case-control study 2016
10 HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know Review 2016
11 Recommended vaccinations for asplenic and hyposplenic adult patients Review 2016
12 Prophylactic HPV vaccination: past, present, and future Review 2016
13 Pneumococcal vaccination in autoimmune rheumatic diseases Review 2017
14 Committee Opinion No. 704: Human Papillomavirus Vaccination Guideline 2017
15 Practice Alert: Advisory Committee on Immunization Practices (ACIP) vaccine update, 2017 Guideline 2017
16 Committee Opinion No. 718: Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis 
Vaccination
Guideline 2017
17 Tdap Vaccination Coverage During Pregnancy - Selected Sites, United States, 2006 - 2015 Retrospective 
observation study
2017
18 Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the 
ACIP
Guideline 2018
19 Infections in Pregnancy and the Role of Vaccines Review 2018
Tdap, tetanus-diphtheria-pertussis; ACIP, advisory committee on immunization practices.
KQ 1. Does vaccination aggravate AIIRD?
Vaccination is unlikely to cause or aggravate AIIRD and generally recommended in 
AIIRD patients (LOE: Low/SOR: Strong recommendation).
administered without worsening underlying diseases, and large-scale epidemiological studies 
also reported that the degree of abnormal responses observed in patients with AIIRD was not 
different from that observed in the general population [18-20].
The live attenuated vaccine is created by reducing the virulence of germs and viruses to 
lower the potential risk of infection while keeping immunogenicity. Unless there is a specific 
prohibition, live attenuated vaccines can be administered to patients with AIIRD who do not 
take immunosuppressive medications. However, since concern exists regarding potential 
severe infections by administering live attenuated vaccines to patients with AIIRD who take 
immunosuppressants, delivering these vaccines to the aforementioned patients should be 
avoided, when feasible. Recently, several biologic agents targeting patients with AIIRD have 
been developed and widely used; however, they must be cautiously administered as they 
lower immunity. The majority of studies also prohibit the administration of live attenuated 
vaccines to patients with AIIRD who are taking immunosuppressants [21-26]. Still, MMR, 
varicella, and herpes zoster vaccines can be restrictively considered depending on the level 
of immunosuppression by performing a risk-benefit analysis for individual patients. The 
risk of infections that may be caused by administering live attenuated vaccines can change 
depending on the type of vaccines and the level of immunosuppression. Herpes zoster 
vaccines can be considered for those who used a steroid for a short period within 2 weeks, 
and were given with a dose of >20 mg of prednisolone per day, a dose of ≥0.4 mg/kg of 
methotrexate per week, and a dose of >3.0 mg/kg of azathioprine per day [23].
Vaccines should be safely administered to patients with AIIRD while keeping 
immunogenicity. Immunosuppressants are not often administered immediately after patients 
are diagnosed with AIIRD. In these cases, live attenuated vaccines can be safely administered 
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KQ 2. Are live attenuated vaccines safe for patients with AIIRD?
KQ 2-1.  Are live attenuated vaccines safe for patients who do not receive 
immunosuppressive therapies?
If AIIRD patients need to take live attenuated vaccines, they have to take vaccination 
while they are not taking immunosuppressive agents (LOE: Very low/SOR: Strong 
recommendation).
KQ 2-2.  Are live attenuated vaccines safe for patients who receive immunosuppressive 
therapies?
AIIRD Patients on immunosuppressive agents should not take live attenuated vaccines 
(LOE: Very low/SOR: Weak against).
KQ 3.  Is a survey on the vaccination history of AIIRD patients helpful in establishing 
treatment strategies?
Once patients are diagnosed with AIIRD, their vaccination history needs to be surveyed 
while treatment strategies are being established (LOE: Expert opinion/SOR: Strong 
recommendation).
to the patients prior to treatment initiation minimizing the reduction of immunogenicity 
caused by immunosuppressants. For this reason, it is important to check the vaccination 
history of patients with AIIRD prior to treatment of immunosuppressants. If any method to 
test antibodies related to target vaccines is available, the test needs to be conducted in the 
early stage of diagnosis and vaccination plans need to be established based on the test results.
Those who treat patients with AIIRD should recommend vaccination, if feasible, prior to 
the planned immunosuppression for proper immunity building and safe vaccination [21-23, 
25, 26]. Since immunogenicity is generally created within 3 weeks after administering live 
attenuated vaccines, it is recommended to administer vaccines 4 weeks prior to planned 
immunosuppression (Table 6) [21]. The recommended timing, however, can differ depending 
on the type of immunosuppressants. When administering live vaccines prior to anti-TNF and 
rituximab therapies, it is recommended to separate them by a 4-week interval, but in the case 
of administering abatacept or tocilizumab, an interval of 2 - 3 weeks is recommended [27-31]. 
Unlike them, inactivated vaccines can be relatively safely administered while administering 
conventional DMARDs or biologic agents [22, 25]. However, since immune responses can be 
slightly different depending on the type of administered immunosuppressive medications, 
vaccinations should be carefully performed. Combination therapies with methotrexate or 
anti-TNF drugs were reported to reduce the immunogenicity of vaccines, while no issue 
associated with the immunogenicity of influenza and pneumococcal vaccines was reported 
in a group to which adalimumab was solely administered [32-34]. While it was reported that 
humoral immune responses were reduced when abatacept was administered, no significant 
effect was observed in the group of tocilizumab [35, 36]. Rituximab, a monoclonal antibody 
against the protein CD20, significantly reduces humoral immune responses due to loss of 
B cells, and for this reason, it is recommended to vaccinate patients at least 4 weeks prior 
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Table 6. Recommended timing of vaccination after discontinuing AIIRD treatment by the type of AIIRD medications
Drug category Medication Half-life period Inactivated vaccine Live attenuated vaccine
Glucocorticoid Prednisone 3 - 4 hours No limitation to vaccinationa 1 month
Synthetic DMARD Methotrexate 3 - 10 hours No limitation to vaccinationa 1 - 3 months
Leflunomide 14 days 3 - 24 months
Biologic DMARD Etanercept 4.3 days No limitation to vaccinationa 1 month
Adalimumab 14 days 3 months
Certolizumab 14 days
Golimumab 12 days
Infliximab 8 - 10 days
Abatacept 13 days 3 months
Tocilizumab 13 days
Rituximab 21 days 6 - 12 months
aAlthough there is no limitation to vaccination, decisions should be made in consideration of the urgency of vaccination and the level of immunosuppression.
AIIRD, autoimmune inflammatory rheumatic disease; DMARD, disease-modifying antirheumatic drugs.
KQ 4.  When should vaccines be administered to patients with AIIRD considering their 
treatment status?
4-1.  Vaccines need to be administered to patients when their AIIRD is in a stable state 
(LOE: Very low/SOR: Strong recommendation).
4-2.  AIIRD patients have to get vaccinated, if feasible, before commencing 
immunosuppressive therapies (LOE: Very low/SOR: Strong recommendation).
to treatment [22, 37]. As such, since immunosuppression can impede immune responses 
after vaccination, vaccination is recommended in general prior to treatment, but it is not 
recommended to delay treatment for AIIRD for completing vaccinations [21].
Since a decrease in the immunogenicity of vaccines caused by immunosuppressive therapies 
is dependent on the total amount of medications that a patient is taking, it would be better 
to administer vaccines to those who have already been receiving immunosuppressive 
therapies when the total amount of medications is the lowest [25]. In addition, the timing 
of administering live attenuated vaccines after discontinuation of immunosuppressive 
therapies differs depending on the type of medications and thus should be determined in 
consideration of the pharmacodynamic characteristics of medications [26]. In general, when 
taking 10 - 20 mg of prednisolone for over 2 weeks, it is recognized as a high-dose steroid, 
and it is recommended to separate discontinuation of the medication and vaccination by a 
4-week interval [38, 39]. When a large amount of medications were intravenously injected, 
it is recommended to suspend vaccination at least for 3 months [38]. When 0.4 mg/kg/week 
or 20 mg/week of methotrexate or more was administered, it is recommended to administer 
vaccines 1-3 months after discontinuation of the medication [25, 40]. In the case of 
leflunomide, due to its long half-life period, it is recommended to separate discontinuation 
of the medication and vaccination by the interval of 3 – 6 months. However, it can remain 
in the body in an activated state for as long as 2 years; therefore, it is recommended to 
administer vaccines 2 years after discontinuation [25, 38, 40]. As etanercept, among anti-TNF 
drugs, has a relatively short half-life period compared to other medications, vaccination can 
be considered 1 month after administering the medication. Conversely, other medications 
including adalimumab, certolizumab, and infliximab should be discontinued for 3 months 
before administering vaccines [25, 38, 40]. In the case of biologic agents like abatacept, 
tocilizumab, and ustekinumab, it is recommended to administer vaccines 3 months (5 
times their half-life period) after discontinuation. Regarding rituximab, however, it is 
recommended to separate discontinuation of the medication and vaccination by the interval 
of 6 - 12 months both for live attenuated vaccines and inactivated vaccines considering the 
recovery period of B cells [22, 25, 26, 28-30].
Immunocompromised patients are more likely than healthy individuals to contract infectious 
diseases when on vacation to places where infectious diseases are endemic. For this reason, 
it is important to consult their doctor regarding vaccination in advance. Since some vaccines 
require multiple doses over a certain period, it is recommended to have a consultation 6 
months before traveling; but, in case of an unexpected vacation, it is necessary to have a 
consultation as early as possible to increase patients' safety and immunogenicity [22]. The 
vaccines that are recommended for those contemplating travel to the aforementioned places 
include hepatitis A and B, influenza, meningococcus, pneumococcus, tetanus, typhoid, 
cholera, rabies, tick-borne encephalitis virus, yellow fever, and MMR vaccines.
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KQ 5.  Is vaccination helpful in preventing endemic diseases for patients with AIIRD 
contemplating international travel?
Patients with AIIRD contemplating travel have to receive vaccines as is generally 
recommended for healthy persons (LOE: Low/SOR: Strong recommendation).
Yellow Fever Vaccination
Yellow fever is an endemic infectious disease in the tropical areas of Africa and the Central 
and South America, having a mortality rate of over 20% due to the absence of an effective 
cure. Therefore, those who contemplate travel to areas where yellow fever is endemic 
are required to receive yellow fever vaccines; however, since these vaccines, compared to 
other live attenuated vaccines, show a high virus replication capacity, patients who receive 
immunosuppressive therapies are not recommended to receive them due to their potential 
risk of infection [25]. In general, it is recommended for patients with AIIRD to avoid travel to 
areas where yellow fever is endemic; but, those who inevitably have to visit such areas should 
write a waiver that states the reason why they cannot be vaccinated [41].
Those who live in households with patients with AIIRD and are immunocompetent should 
be vaccinated according to the Korean guideline for vaccination. They should be vaccinated 
against influenza every year, and MMR, rotavirus, varicella, and herpes zoster vaccines should 
be administered according to their general recommendations [42-48]. In some cases, yellow 
fever and oral typhoid vaccines should be administered if necessary. However, as live vaccines 
can spread viruses after administration, those who received such vaccines, in general, need 
to be careful when in contact with patients who are receiving immunosuppressive therapies, 
for 2 weeks following vaccination. If there is any family member who was vaccinated against 
rotavirus, patients with AIIRD should avoid contacting the vaccinated family member's feces 
for 4 weeks and should maintain hand hygiene.
VACCINATION RECOMMENDATIONS BY VACCINE
1. Influenza vaccine
1) Vaccination targets
All patients with AIIRD should be vaccinated against influenza. There are only a few 
epidemiological studies on influenza infection targeting patients with AIIRD. A study that 
targeted individuals aged ≥65 years reported that the number of those who were hospitalized 
due to influenza infections and complications increased in the group of patients with chronic 
diseases including rheumatoid diseases and vasculitis [49]. A retrospective study, targeting 
46,030 patients with rheumatoid arthritis reported that their influenza infection rate was 
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KQ 6.  Should those who live in a household with patients with AIIRD and their caregivers 
receive vaccines?
Those who live in households with patients with AIIRD and their caregivers have to 
receive generally recommended vaccines. In particular, influenza, measles-mumps-
rubella (MMR), varicella, and herpes zoster vaccines need to be administered based on 
the same schedules for healthy persons (LOE: Moderate/SOR: Strong recommendation).
Patients with AIIRD have to take influenza vaccines every year (LOE: Moderate/SOR: 
Strong recommendation).
high (409.33 vs. 306.12 persons/100,000 patients-days) and that the rate of complications 
was 2.75 times higher [50]. No relationship was observed between the increasing rates and 
the medications used for the patients. In general, since patients with AIIRD are judged to 
be more likely to contract influenza and complications, it is recommended to administer 
influenza vaccines to all patients with AIIRD, and most guidelines also recommend influenza 
vaccines as the highest priority vaccine.
2) Effects and efficacy of vaccine
The immunogenicity of patients with rheumatoid arthritis is similar to that of healthy 
individuals, and immunogenicity can be maintained even when conventional synthetic 
DMARDs (csDMARDs) or anti-TNF drugs [34, 51-61] are administered. It has often been 
reported that the immunogenicity of patients with lupus is slightly decreased, and many 
studies reported no significant differences in immunogenicity between patients with lupus and 
healthy individuals [18, 20, 57, 62-70]. Patients with granulomatosis with polyangiitis, systemic 
sclerosis, and Sjogren's syndrome were also reported to show no differences in immunogenicity 
compared to healthy persons [19, 71-73]. Only few studies exist, regarding the effects of 
influenza vaccines on patients with AIIRD; however, a large-scale observational study that 
targeted patients with rheumatoid arthritis reported that the infection rate of the vaccinated 
group decreased by 17% (95% confidence interval [CI], 5 - 29%) [74]. Another study that 
targeted patients with rheumatoid arthritis and systemic erythematosus lupus also reported 
that the share of those who contracted pneumonia, acute bronchitis, and virus infection in the 
vaccinated group was significantly lower than that of the non-vaccinated group [74, 75]. The 
immunogenicity of influenza vaccines can differ, depending on the use of immunosuppressants 
and the type of medications. However, it was reported that the immunogenicity of patients with 
AIIRD was generally similar to or slightly lower than that of healthy individuals.
3) Safety of vaccine
Inactivated influenza vaccines can be safely administered, even in an immunocompromised 
state. Their side effects in patients with AIIRD are not different from those in healthy persons 
[51, 57].
4) Vaccination methods
Since protective immunity to influenza can be sufficiently achieved when influenza vaccines 
are administered before influenza is prevalent, influenza vaccines should be administered 
prior to the prevalence of influenza, and even amid the prevalence of influenza, patients 
should be vaccinated as early as possible. In Korea, influenza is prevalent from November 
to April. A dose of intramuscular injection is administered in general, but the methods 
of administration can differ depending on the dosage of vaccines. Therefore, they should 
be administered following their respective instructions. When patients are receiving 
immunosuppressants, the timing of vaccination should be determined, considering the 
patients' disease, immunosuppression level, and half-life period of the medications.
2. Pneumococcal vaccine
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Patients with AIIRD have to take pneumococcal vaccines (LOE: Low/SOR: Strong 
recommendation).
1) Vaccination targets
Streptococcus pneumoniae accounts for about 30 - 40% of community-acquired pneumonia. The 
infection of S. pneumoniae can cause severe complications or death particularly in persons 
aged ≥65 years, patients with chronic diseases, and immunocompromised patients. Although 
epidemiological data available on the infection of S. pneumoniae in patients with AIIRD are 
sufficient, it was reported that patients who used anti-TNF drugs showed a 5 times higher 
incidence of pneumonia (5.97/1,000 vs. 1.07-1.2/1,000 patients-days) than healthy persons 
[76]. The mortality rate of patients with rheumatoid arthritis from pneumonia increased 
by 2 - 5 times and the hospitalization rate of patients with rheumatoid arthritis is 2 times 
higher than that of general persons [77]. Since the share of those who contract infections and 
complications caused by S. pneumoniae among patients with AIIRD increases, all patients with 
AIIRD are recommended to be vaccinated against S. pneumoniae.
2) Effects and efficacy of vaccine
In general, the effects of S. pneumoniae vaccines on patients with AIIRD are nearly identical to 
those on healthy persons [78-84]. As for the effects of medications administered to patients 
with AIIRD on the immunogenicity of vaccines, csDMARDs did not show any effect, while 
methotrexate, rituximab, and abatacept were reported to decrease immunogenicity. The 
immunogenicity of pneumoccal vaccines differed depending on the type of anti-TNF drugs 
in early studies. In a randomized controlled trial that studied the effect of a pneumococcal 
polysaccharide vaccine 23 (PPSV23) in patients with rheumatoid arthritis, the effect of 
pneumonia prevention was unclear. However, it was conducted on a small number of 
patients with a severe immunocompromised condition. Furthermore, some reports show 
reduced immunogenicity in some patient groups. Therefore, efforts to optimize the effects 
such as adjusting the timing of inoculation are necessary [85].
3) Safety of vaccine
Pneumococcal vaccines, as inactivated vaccines, can be administered regardless of the state 
of immunity, and do not affect the activity of AIIRD. No valid epidemiological study has been 
conducted yet regarding the safety of pneumococcal vaccines for patients with AIIRD [77]. 
It was reported that the aluminum salts used as a vaccine adjuvant may cause fever, pain at 
the injection site, and malaise and can cause autoimmune/inflammatory syndrome induced 
by adjuvants (ASIA); however, no study has been reported on streptococcal vaccines [86]. 
Yet, it was reported that both strong local and excessive systemic inflammatory responses 
were observed in patients with Behcet's disease after vaccination, thus making it necessary 
to carefully observe patients after vaccination [87]. Another study reported that abnormal 
responses to pneumococcal vaccines were observed in infants who were less than 1 year old 
and had Kawasaki disease [88].
4) Vaccination methods
As of 2019, 2 pneumococcal vaccines are available for adults: pneumococcal conjugate 
vaccine 13 (PCV13) and PPSV23. PCV13 shows good immunogenicity and also proved to be 
effective in preventing pneumonia in healthy adults. The finding that it is cost-effective to give 
both vaccines to high-risk patients of pneumococcal infection is true; therefore it is safe to 
administer both the PCV13 and the PPSV23 to adult patients with AIIRD [89]. A booster effect 
is caused when administering the PCV13 first, while a hypo-responsiveness is caused when 
administering the PPSV23 first; therefore, it is advisable to administer the PCV13 first [90].
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①  Unvaccinated patients against pneumococcal vaccines: A dose of PCV13 should be 
administered first, and 1 dose of PPSV23 should be administered at least 8 weeks later. 
A dose of PPSV23 should be additionally administered 5 years after the last vaccination.
②  Patients who were administered with 1 dose of PPSV23: A dose of PCV13 should be 
administered 1 year after the administration of PPSV23. A dose of PPSV23 should be 
additionally administered at least 8 weeks after the administration of PCV13 and 5 years 
after the previous administration of PPSV23.
③  Patients who were administered with 2 doses of PPSV23: A dose of PCV13 should be 
administered 1 year after the last vaccination.
④  Patients who were administered with a dose of PCV13 and 2 doses of PPSV23 before the 
age of 65: A dose of PPSV23 should be additionally administered after turning 65, and 5 
years after the previous administration of PPSV23.
3. Hepatitis B vaccine
1) Vaccination targets
The use of immunosuppressants in patients with AIIRD is likely to reactivate hepatitis B, 
causing a high risk of complications [91-93]. A retrospective study that targeted 123 HBsAg-
positive patients with rheumatoid arthritis reported that hepatitis B was reactivated in 30 
patients (24.4%) during treatment [94]. Multiple guidelines related to the vaccination of 
patients with AIIRD also recommend to vaccinate patients with AIIRD with no hepatitis 
B antibody (all HBsAg, anti-HBc, and anti-HBs-negative) and unvaccinated individuals. 
Hepatitis B vaccines are more actively recommended for high-risk groups. The guidelines 
published by the KSID and the Korean Association for the Study of the Liver, the American 
College of Rheumatology, and the Canadian Rheumatology Association define hepatitis 
B high-risk groups as: those who abuse injection drugs; those who have sexual relations 
with multiple partners; those who travel or stay for a long time in areas where hepatitis 
B is prevalent; those who are frequently administered with blood components; male 
homosexuals; those who contact patients with hepatitis B; health care providers and 
laboratory workers who can be exposed to the hepatitis B virus [95, 96]; patients with AIIRD 
who are being administered with biologic agents such as TNF-blockers and rituximab; and 
immunocompromised patients who are receiving high-dose steroid therapies [21].
2) Effects and efficacy of vaccine
It is generally recognized that the preventive effect of hepatitis B vaccines can be achieved 
when the serum antibody reaches 10 IU/L after vaccination. When patients with AIIRD who 
had no hepatitis B antibody (all HBsAg, anti-HBc and anti-HBs-negative) were administered 
with 3 doses of hepatitis B vaccines (0, 1, and 6 months), a relatively large percentage 
(68 – 93%) showed an effective seroconversion rate. However, since those who are being 
administered with csDMARDs, biologic agents, and rituximab show a low seroconversion 
rate (70%, 50%, and 25% respectively), the generation of antibodies in those who receive 
immunosuppressants should be monitored after vaccination [97]. To monitor the generation 
of antibodies, the potency of anti-HBs antibodies should be measured 4-6 weeks after 
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AIIRD patients who have no hepatitis B antibody have to take Hepatitis B vaccines (LOE: 
Low/SOR: Strong recommendation).
the last vaccination. In the case that antibodies are not generated against hepatitis B after 
vaccination, it is recommended to administer 3 doses of hepatitis B vaccines (0, 1, 6 months).
Vaccination is expected to benefit patients with AIIRD at some extent, who are positive only 
for anti-HBc (negative for HBsAg and anti-HBs) thus suspecting a past hepatitis B virus 
exposure; however, no consistent practice guidelines are available that support it [98]. For 
those who are positive only for anti-HBc, the HBV DNA test should be performed to identify 
whether the state is false positive or latent infectious, and, if negative, vaccination can be 
considered [99].
3) Safety of vaccine
Inactivated hepatitis B vaccines can be safely administered when immunity is compromised. 
The side effects of hepatitis B vaccination in patients with AIIRD are not different from those 
in healthy persons. A study that compared 44 patients with rheumatoid arthritis with healthy 
controls reported no difference in the frequency of abnormal responses to vaccination [97, 
100]. Moreover, there is no study reporting that hepatitis B vaccines worsen AIIRD.
4) Vaccination methods
A 3-dose series (0, 1, and 6 months) of hepatitis B vaccines should be administered to 
patients with AIIRD who have no hepatitis B antibody. To non-responding patients not 
showing any sign of antibodies after administering 3 doses, it is recommended to administer 
another 3 doses of (0, 1, and 6 months). No clear evidence yet exists of an accelerated 
schedule of hepatitis B vaccines (for instance, 0, 1, 2, and 12 months) or a high dose 
immunization for patients with AIIRD.
4. Hepatitis A vaccine
1) Vaccination targets
There is no evidence that patients with AIIRD are more vulnerable to hepatitis A or have 
a higher risk of complications. Almost no statement regarding hepatitis A vaccination 
was observed in the guidelines for the vaccination of patients with AIIRD that was either 
published in-country or abroad [22, 23]. However, it is generally recommended to administer 
hepatitis A vaccines to patients with AIIRD based on the same indication of healthy 
individuals. The KSID recommends administering hepatitis A vaccines to patients with 
chronic diseases; workers in childcare facilities; health care providers and laboratory workers 
in danger of being exposed to hepatitis A virus; restaurant workers; those who travel to or stay 
for a long time in areas where hepatitis A is prevalent; those who are frequently administered 
with blood components; male homosexuals; those who abuse narcotic injections; and those 
who contact patients with hepatitis A [96]. Considering the epidemiology of hepatitis A in 
Korea, it is recommended to administer vaccines to those aged <40 years without an antibody 
test, and to those aged ≥40 years only after conducting an antibody test and confirming that 
they are antibody-negative [101].
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Hepatitis A vaccines should be considered for patients with AIIRD based on the same 
indication of healthy persons (LOE: Low/SOR: Weak recommendation).
2) Effects and efficacy of vaccine
The aforementioned research findings indicate that the immunogenicity of patients 
with AIIRD is not significantly lower than healthy individuals. Yet, those who are taking 
immunosuppressant therapies may show lower immunogenicity; therefore, hepatitis A 
vaccines should be administered, if feasible, prior to or following the administration of 
immunosuppressants. If the risk of infection is high due to exposure to the hepatitis A virus, 
hepatitis A vaccines should be administered even during immunosuppressive therapies.
3) Safety of vaccine
The indicated hepatitis A vaccines can be safely administered even in an 
immunocompromised state. Their side effects in patients with AIIRD are not different from 
those in healthy individuals [102].
4) Vaccination methods
In general, intramuscular injections are administered according to the instructions of the 
products. After the first vaccination, the second dose should be administered within 6 - 18 
months. When patients are receiving immunosuppressants, the timing of vaccination should 
be determined considering the disease conditions of patients, the immunosuppression level, 
and the medications' half-life period.
5. Human papillomavirus vaccine
1) Vaccination targets
A multi-center cross-sectional study conducted in Korea reported that patients with 
systemic lupus erythematosus showed a higher-risk human papilloma virus infection 
rate (24.6% vs. 7.9%, Odds ratio [OR] 3.8) and a higher frequency of abnormalities in 
the results of a Pap smear test (16.4% vs. 2.8%, OR 4.4) than a control group [103]. The 
systemic lupus erythematosus itself was an independent risk factor of the observed 
abnormalities (OR 3.5, 95% CI 1.8 - 6.9), and there was no significant correlation with the 
use of immunosuppressants. The overall prevalence of HPV in patients with systemic lupus 
erythematosus was higher (11.8% vs. 7.3%), and that of multiple infections of HPV in patients 
with lupus was also higher (4.7% vs. 1.1%) [104]. Whereas, the viru's removal rate in patients 
with systemic lupus erythematosus was lower than that of a general group [105]. HPV 
vaccines are recommended for young adults with AIIRD, particularly females aged between 
13 and 16 years before having their first sexual contact, and no later than the age of 26 years 
[23, 25, 106]. In the United States, HPV vaccines are allowed to be administered by the age 
of 45 years, but for those aged >26 years, vaccination should be determined considering their 
sexual contact history and immunosuppressive state. Patients with rheumatoid arthritis who 
are taking immunosuppressants, including biologic agents, are recommended to receive HPV 
vaccines when they are adapted [95]. Young male patients with AIIRD are also recommended 
to receive HPV vaccines should they have no vaccination history. Since many clinical studies 
reported that patients with systemic lupus erythematosus contracted HPV, vaccination 
should be highly considered.
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Patients with AIIRD must be administered human papillomavirus (HPV) vaccines (LOE: 
Low / SOR: Strong recommendation).
2) Effects and efficacy of vaccines
The seroprevalence rate of HPV vaccines in patients with systemic lupus erythematosus is 
76%, which is lower than that of unaffected individuals (93%). Those who were administered 
with a low-dose steroid showed significantly low potency of HPV-16 antibodies compared 
to those who were not administered with steroid (1870 mMU vs. 3818 mMU), and patients 
with systemic lupus erythematosus who were administered with the mycophenolate mofetil 
immunosuppresant tended to show a lower potency of HPV-6,-16,-18 antibodies [107]. These 
research results indicate that administrating immunosuppressants, such as steroids and 
mycophenolate mofetil, can lower the HPV's immunogenicity.
3) Vaccine safety
Inactivated HPV vaccines can be safely administered to patients with AIIRD regardless of 
their immunity state or the use of immunosuppressants. A recent case-control study that 
assessed the efficacy and safety of HPV vaccines in patients with systemic lupus erythematosus 
reported that there was no change in the activity of systemic lupus erythematosus for 1 year 
after vaccination [107]. The frequency and severity of abnormal responses were not different 
from healthy individuals, while there is no sufficient evidence that they worsen AIIRD. It was 
reported that blood clots were created after vaccination (relative risk, 0.2/100,000); however, 
most cases had a relevant risk factor [108]. Patients with antiphospholipid antibody syndrome 
need to be carefully observed after administering vaccines.
4) Vaccination methods
A primary series of HPV vaccines should be administered to female children aged between 
11 and 12 years. For those not vaccinated or with an incomplete 3-dose primary series, it is 
recommended to administer an HPV 4 or HPV 9 vaccine to females aged between 13 and 
26 years and an HPV 2 vaccine to females aged between 13 and 25 years. In Korea, a three-
dose series of human papilloma virus vaccines is recommended. The second dose should 
be administered 1 or 2 months after the first, and the third dose should be administered 6 
months after the second. The first and second doses should be separated by at least 4 weeks, 
and the second and third doses should be separated at least by 5 months. Those who did not 
receive the second and third doses after the first dose and thus did not complete vaccination 
do not need the series again from the first dose, and additional doses should be administered 
according to the recommended vaccination schedule. In this case, they can be vaccinated 
even after their 26th birthday. Those who are taking immunosuppressants, including biologic 
agents, can also be administered HPV vaccines; but, vaccination is recommended when the 
disease's activity is stabilized.
6. Tetanus-diphtheria-pertussis vaccine
1) Vaccination targets
Patients with AIIRD should be vaccinated against tetanus-diphtheria-pertussis, according 
to the general recommendations. When a contaminated injury was found in patients who 
received a rituximab therapy within the last 24 weeks, immunoglobulin is administered for 
passive immunity [23].
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Patients with AIIRD have to take tetanus-diphtheria-pertussis vaccines (LOE: Moderate/
SOR: Strong recommendation).
2) Effects and efficacy of vaccine
It is known that the immunogenicity of tetanus vaccines in patients with rheumatoid arthritis 
or systemic lupus erythematosus is lower than that of healthy individuals regardless of the 
administration of immunosuppressants [109]. There are various ways in which a decrease in the 
immunogenicity of vaccines caused by the use of immunosuppressants is observed, depending 
on the type of administered immunosuppressants. A slight decrease was observed in the case 
of methotrexate compared to healthy persons; however, the immunogenicity of vaccines in 
those who received combination therapies with methotrexate and rituximab was similar to the 
immunogenicity in those who were only administered methotrexate [110]. Although there was 
no study on patients with rheumatoid arthritis, the immunogenicity of healthy individuals who 
were administered tetanus vaccines 2 weeks after administering abatacept was reduced [111]. 
Those who were administered tetanus vaccines 8 weeks after administering abatacept showed 
similar immunogenicity compared to those who were administered with tetanus vaccines 2 
weeks after receiving abatacept; but, the level was lower than that of those who did not receive 
abatacept. Patients with rheumatoid arthritis who were administered methotrexate and 
tocilizumab showed no significant difference regarding the immunogenicity of tetanus vaccines 
compared to those who were only administered methotrexate [36]. Some studies reported that 
the effects of tetanus-diphtheria-pertussis vaccines decreased in patients with systemic lupus 
erythematosus who showed high disease activity, but others reported opposite results, thus 
requiring an additional study [78, 84, 112, 113].
3) Safety of vaccine
Tetanus-diphtheria (Td) vaccines for adults and inactivated tetanus-diphtheria-pertussis 
(Tdap) vaccines, can be safely administered to patients with AIIRD, regardless of their state 
of immunity or use of immunosuppressants. The frequency and severity of side effects are 
not different from that of healthy individuals, with no evidence that vaccination increases the 
activity of rheumatoid arthritis or systemic lupus erythematosus [84].
4) Vaccination methods
Td and Tdap vaccines can be administered to patients with AIIRD based on the same 
schedules for general adults. Adults aged 18 years or older who are not vaccinated with 
childhood DTP (Diphtheria toxoid, whole cell pertussis, and tetanus toxoid vaccine), who 
have no clear vaccination record, or who were born before 1958 (when domestic DTP was 
introduced) should be administered with 3 doses. The Tdap vaccine should be administrated 
first, and additionally given with the Td vaccine after 4 - 8 weeks and 6-12 months. If the Td 
vaccine is primarily administrated, then the second or third schedule constitutes the Tdap 
vaccine. Thereafter, the Td vaccine should be additionally administered every 10 years. 
Pregnant women should be given a Tdap vaccine every 27 – 36 weeks of pregnancy, regardless 
of the previous Td vaccine history or a Tdap vaccine to prevent pertussis in newborns.
7. Herpes Zoster Vaccine
1) Vaccination targets
The risk of herpes zoster infection in patients with AIIRD is increased by immunosuppressants 
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Herpes zoster vaccines should be considered for patients with AIIRD who are aged ≥50 
years (LOE: Very low/SOR: Weak recommendation).
or immune dysregulation. Not many epidemiological studies have been conducted on 
patients with AIIRD, but the risk of herpes zoster infection in patients with rheumatoid 
arthritis, systemic lupus erythematosus, granulomatosis with polyangiitis, polymyositis 
and dermatomyositis is known to be higher than healthy individuals [114]. The KSID fully 
recommends to administer herpes zoster vaccines to adults aged ≥60 years regardless of their 
history of herpes zoster. In addition, it is recommended to determine whether to administer 
herpes zoster vaccines to adults aged 50 - 59 years based on the conditions of individuals. 
Most practice guidelines for patients with AIIRD published in other countries recommend 
to administer herpes zoster vaccines to patients with AIIRD who are aged ≥60 years and are 
not severely immunocompromised [23, 26, 95]. Guidelines in Europe and the Centers for 
Disease Control and Prevention (CDC) of the United States state that herpes zoster vaccines 
can be administered even when using a low dose of methotrexate (<0.4 mg/kg/week or <20 
mg/week), glucocorticoid (prednisolone, <20 mg/day), azathioprine (<3.0 mg/kg/day) and 
6-mercaptopurine (<1.5 mg/kg/day).
2) Effects and efficacy of vaccines
No prospective study exists regarding the clinical effects and safety of herpes zoster vaccines 
on patients with rheumatoid arthritis. Two large-scale retrospective studies were conducted 
regarding the effects of the herpes zoster vaccines on patients with AIIRD, including those 
who were administered with biologic agents. Their results reported that the prevalence of 
herpes zoster in those who were administered the vaccines was similar to the prevalence in 
those who did not; however, the risk of herpes zoster was reduced by 39% (29 - 48%) [115, 
116]. Another retrospective study reported that those who were administered the herpes 
zoster vaccines showed a lower prevalence than those who were not; however, they found 
that the effects disappeared 5 years after vaccination [117]. A prospective pilot study targeting 
10 patients with systemic lupus erythematosus also reported that their immunogenicity was 
slightly reduced, but was not significant [118].
3) Safety of vaccine
Herpes zoster vaccines that are currently distributed are live attenuated; thus, it should be 
carefully administered to those who receive immunosuppressants. Guidelines in Europe and 
the CDC of the United States state that herpes zoster vaccines can be administered even when 
using a low dose of methotrexate (<0.4 mg/kg/week or <20 mg/week), glucocorticoid (<20 
mg/day prednisolone or equivalent), and azathioprine (<3.0 mg/kg/day). However, herpes 
zoster vaccines should not be administered to those who receive a high-dose steroid or 
immunosuppressant or a low dose of more than 2 types of immunosuppressants or biologic 
agents (adalimumab, infliximab, etanercept, etc.).
4) Vaccination methods
Herpes zoster vaccines that are currently distributed in Korea are one-time subcutaneously 
administered. The biggest issue regarding the herpes zoster vaccines is the emergence 
of Shingrix® (GlaxoSmithKline Biologicals, Rixensart, Belgium), the recombinant zoster 
vaccine. The vaccine is yet to be introduced in Korea, and it will be a while before it is 
distributed. The two-dose series of Shingrix® are intramuscularly injected, and, as the vaccine 
is inactivated, it is expected to remedy the disadvantages of live attenuated vaccines. The 
Advisory Committee on Immunization Practices (ACIP) in the United States recommends 
Shingrix® administration to patients with rheumatoid arthritis. It has, however, deferred 
recommending Shingrix® for immunocompromised patients or those who are receiving 
moderate or severe immunosuppressants [119].
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8. Measles-Mumps-Rubella Vaccine
1) Vaccination targets
Live attenuated vaccines must not be administered to patients with AIIRD who are taking 
immunosuppressants; however, when the level of immunosuppressive therapies is low, MMR 
vaccines can be considered [23]. Epidemiological studies on MMR infections in patients with 
AIIRD are rare. Korea was certified by the World Health Organization as the country that 
eradicated measles in 2014. However, imported cases of measles have been intermittently 
reported. Since it is generally known that the risk of MMR infections and complications in 
patients with AIIRD is high, it is recommended to administer MMR vaccines to patients with 
AIIRD considering the state of immunity and the type of medications used when the risk of MMR 
infection is high and the risk of infections caused by live attenuated vaccines is low [23, 120].
2) Effects and efficacy of vaccine
The efficacy of MMR vaccines on patients with AIIRD has not been researched. Studies 
that targeted patients with juvenile arthritis reported both a maintained immunogenicity 
well after vaccination and the ineffectiveness of biologic agents including methotrexate 
and anti-TNF drugs on immunogenicity [121, 122]. In conclusion, the immunogenicity of 
MMR vaccines can differ depending on the use of immunosuppressants and the type of 
medications; but, the level is generally assumed to be similar to or slightly lower than that of 
healthy individuals.
3) Safety of vaccine
Administering MMR vaccines should be avoided, if feasible, to those who are using biologic 
agents and immunosuppressants or to patients with AIIRD who are immunocompromised. This 
is due to the immunocompromised persons administered with live attenuated vaccines being 
infected by vaccine injections [123]. Unlike herpes zoster vaccines, the possibility of vaccination 
depending on the use and the dose of immunosuppressants are not mentioned in detail.
4) Vaccination methods
Administering the MMR vaccines to those who are contemplating travel to countries where 
measles is prevalent but whose level of immunity is uncertain is recommended. It should 
be determined whether to administer the vaccines to patients with AIIRD after checking 
their vaccination history, use of immunosuppressants, and an immunocompromised state. 
After checking their vaccination history (not necessary to vaccinate those who contracted 
measles in the past or those whose measles antibodies are positive or those aged ≥51 years), 
those who did not complete a 2-dose series of MMR vaccines or those who are not certain 
about their vaccination history are recommended to be administered with a 2-dose series 
of vaccines (at least 4 weeks apart) before traveling. Patients with AIIRD who are expecting 
pregnancy should be tested for rubella antibodies and if they are found to be antibody 
negative, they should be administered with vaccines. Still, it is recommended to administer 
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AIIRD patients on biologics agents or immunosuppressants should avoid measles-
mumps-rubella (MMR) vaccines (LOE: Very low/SOR: Weak against).
MMR vaccines can be considered for those who have not been vaccinated, depending on 
the risk of being exposed to MMR virus (LOE: Very low/SOR: Weak recommendation).
vaccines at least 4 weeks prior to initiating immunosuppressive therapies. For those who are 
using immunosuppressants, the timing of vaccination should be determined considering the 
disease conditions of patients, and the immunosuppression level and the half-life period of 
the immunosuppressants.
DISCUSSION AND CONCLUSIONS
This practice guideline was developed to present the types of vaccines and the methods of 
vaccination suitable for Korean patients with AIIRD. This guideline is intended for clinicians 
and primary care providers. A practice guideline development committee was formed to 
review existing guidelines and adapt them to develop a proper guideline.
The content of this practice guideline is not far different from that of the existing practice 
guidelines. Since vaccination is the most effective way to prevent infectious diseases and 
the possibility that vaccinations may aggravate AIIRD is low, vaccinations should be actively 
considered for patients with AIIRD based on the guideline for vaccination of persons who are 
healthy and whose level of immunity is normal. To do so, the vaccination history of patients 
should be checked prior to initiating AIIRD treatment, and it is recommended to vaccinate 
them, if feasible, prior to the use of immunosuppressants. Most inactivated vaccines can 
be safely administered, but live attenuated vaccines should be avoided for patients with 
AIIRD who use immunosuppressants as much as possible. In addition, those who live in a 
household with patients with AIIRD and their care providers should be vaccinated based on 
the vaccination instructions for healthy individuals.
One of the limitations of these guidelines is the lack of evidence for developing this practice 
guideline. The prevalence of AIIRD itself is low and the immunosuppression level and 
health conditions of patients differ. There are also various types of medications used to 
treat underlying diseases. For this reason, only a few high-quality randomized controlled 
studies have been conducted, making it difficult to systematically conduct a literature review. 
Moreover, there is almost no study that surveyed the vaccination status of Korean patients 
with AIIRD or analyzed the effects and impact of vaccines. Moreover, the opinions and needs 
of different groups were not reflected in the process of developing this practice guideline. 
Involving users in the process of developing and writing a guideline is effective in raising 
their sense of responsibility for, and inducing their interest in the developed guideline. For 
this reason, professionals in the field, such as doctors at general hospitals, practitioners, 
and nurses should be engaged in the process of development. It is also necessary to involve 
and collect feedback from patients in the process. Third, the applicability of this practice 
guideline was not sufficiently reviewed. The unique characteristics of the Korean health care 
systems were not sufficiently considered, and its applicability was not analyzed due to limited 
resources; therefore, the cost-effectiveness of vaccinations was not analyzed. Additionally, 
the distribution and implementation methods of this guideline were not discussed.
This is the first practice guideline regarding the vaccination of patients with AIIRD; 
therefore, it needs to be periodically revised, considering that new AIIRD medications 
continue to be developed and that new vaccines are also introduced.
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